Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Syphilis Treatment Drugs Market size is expected to register remarkable growth rate during the forecast period i.e., between 2025-2037.
The growth of the syphilis treatment drugs market can be attributed to growing number of incidences of unprotected sex, anonymous sex and intercourse under the influence of drugs. According to the United States Centers for Disease Control and Prevention (CDC), in 2019, nearly 46% of sexually active high school students did not use a condom the last time they had sex. Half of the cases of STD are reported among people aged between 15-24 years. In addition to these, growing prevalence of syphilis in developing nations is also expected to drive market growth in the near future. Furthermore, as the prevalence of sexually transmitted diseases (STDs) is increasing, the sales of treatment drugs are also evaluated to witness a major surge in the coming years, which in turn is assessed to boost the market growth.
Syphilis Treatment Drugs Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Incidences of Unprotected Sex Worldwide
- Growing Occurrence of Syphilis in Developing Nations
Challenges
- Lack of Trained Laboratory Personnel in Under Developed Nations
Syphilis Treatment Drugs Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
|
|
|
|
|
|
|
|
|
Regional Scope |
|
Syphilis Treatment Drugs Segmentation
The market is segmented by disease type into primary, secondary, tertiary syphilis, and others, out of which, the primary and secondary syphilis segments are anticipated to hold the largest share in the syphilis treatment drugs market on account of the commonness of the disease in its earlier and transmissible stages. Additionally, majority of the cases of primary and secondary syphilis occur among homosexual men. Another report by the CDC states, in 2019, of the total syphilis cases, 38,992 were of primary and secondary (P&S) syphilis. Out of these, 56% of the total incidents accounted for all male cases. Rising openness towards same-sex is also estimated to offer opportunities to the growth of this market segment in the near future. Moreover, based on distribution channel, the segment for hospital pharmacies is evaluated to occupy the largest market share during the forecast period, which can be credited to the ease to receive prescribed medicines from the hospital facility itself.
Our in-depth analysis of the global market includes the following segments
|
By Disease Type |
|
|
By Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportSyphilis Treatment Drugs Industry - Regional Synopsis
North America Market Statistics
North America industry is predicted to hold largest revenue share by 2037, on the back of high awareness about the disease, favorable public health insurance plans and growing advancements in the healthcare sector, on the back of high awareness about the disease, favorable public health insurance plans and growing advancements in the healthcare sector.
Europe Market Analysis
Europe is also assessed to acquire a large share in the syphilis treatment drugs market during the forecast period owing to the rising R&D activities to develop effective treatment for STDs in the region. However, the market in the Middle East & Africa is projected to witness noteworthy growth over the forecast period, which can be ascribed to increasing occurrence of syphilis in Africa, emergence of new point-of-care (POC) testing concepts and increasing number of public health labs to provide STD testing. According to the World Health Organization (WHO), Africa accounted for the highest prevalence of syphilis in the world.
Companies Dominating the Syphilis Treatment Drugs Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- GlaxoSmithKline plc
- Johnson & Johnson Services, Inc.
- F. Hoffman-La Roche Ltd
- Abbott Laboratories
- PerkinElmer, Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- Sandoz GmbH
In the News
Author Credits: Radhika Pawar
- Report ID: 3072
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
